2,4-Diisopropyl-1,3,5-triazin | 57249-36-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2,4-Diisopropyl-1,3,5-triazin
• 英文别名: 2,4-diisopropyl-[1,3,5]triazine；2,4-Diisopropyl-1,3,5-triazine；2,4-di(propan-2-yl)-1,3,5-triazine
• CAS: 57249-36-2
• 化学式: C₉H₁₅N₃
• 分子量: 165.238
• InChiKey: QMKFJBLLSBFMIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异丁醛 、 乙醛 生成 2,4-Diisopropyl-1,3,5-triazin
  参考文献：
  名称：

  BECKER B. F.; FRITZ H. P., CHEM. BER. , 1976, 109, NO 4, 1346-1352 D2-#5#; #99# #2#4

  摘要：

  DOI：

文献信息

• Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
  申请人：Gaul Michael D.

  公开号：US20090069305A1

  公开（公告）日：2009-03-12

  The present invention relates to substituted nitrogen-containing heteroaryl derivatives, pharmaceutical compositions containing them, and methods of using any of these derivatives and compositions for H 4 receptor activity modulation and the treatment of states mediated by histamine H 4 receptor activity.

  本发明涉及取代的含氮杂芳基衍生物、含有它们的药物组合物，以及使用这些衍生物和组合物中的任一种用于调节H4受体活性和治疗由组胺H4受体活性介导的状态的方法。
• Substituted Imidazo[2,1-b]thiazole Compounds and Uses Thereof
  申请人：KUEHNERT Sven

  公开号：US20090005399A1

  公开（公告）日：2009-01-01

  Substituted imidazo[2,1-b]thiazole compounds corresponding to formula I, a method for producing them, pharmaceutical compositions containing them, and the use thereof for regularing mGluR5 receptors, or for treating or inhibiting disorders or disease states at least partially mediated by mGluR5 receptor such as pain, anxiety attacks, drug or alcohol dependency, and others.

  替代imidazo[2,1-b]噻唑化合物对应于公式I，一种生产它们的方法，含有它们的药物组合物，以及将其用于调节mGluR5受体，或用于治疗或抑制至少部分由mGluR5受体介导的疾病或疾病状态，如疼痛、焦虑发作、药物或酒精依赖等。
• SUPRAMETALLOGELS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20150225438A1

  公开（公告）日：2015-08-13

  The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

  该披露提供了通过过渡金属配体（例如Pd(II)-、Ni(II)-或Fe(II)-配体的A式）协调和连接自组装形成的纳米结构（例如纳米球和纳米桨轮）。该披露还提供了由二价连接剂Y连接的纳米结构的超分子复合物。提供的超分子复合物能够形成凝胶（例如水凝胶）。这些凝胶是超金属凝胶，具有出色的机械性能，不会牺牲自愈能力，并展现出高韧性和储存模量。本披露还提供了包括纳米结构或超分子复合物以及可选药剂（例如小分子）的组合物（例如凝胶），其中纳米结构和超分子复合物的纳米结构部分可以包裹并缓慢释放药剂。这些纳米结构、超分子复合物和组合物可用于将药剂输送至受体、组织或细胞，作为超吸水材料，并用于治疗疾病（例如遗传疾病、增生性疾病（例如癌症或良性肿瘤）、血液疾病、神经系统疾病、胃肠疾病（例如肝病）、脾脏疾病、呼吸系统疾病（例如肺部疾病）、疼痛症状、泌尿生殖系统疾病、肌肉骨骼状况、传染病、炎症性疾病、自身免疫疾病、精神障碍或代谢性疾病）。
• [EN] NOVEL PROTEIN KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE PROTÉINES KINASES
  申请人：TENOVA PHARMACEUTICALS INC

  公开号：WO2021216440A1

  公开（公告）日：2021-10-28

  The present disclosure describes novel protein kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such protein kinase inhibitors and methods of using them for treating cancer and other diseases, conditions, or disorders, which respond to the inhibition of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) activity, or a combination thereof, are also described.

  本公开描述了新型蛋白激酶抑制剂以及其制备方法。还描述了包含这种蛋白激酶抑制剂的药物组合物，以及使用它们治疗对表皮生长因子受体（EGFR）、间变性淋巴瘤激酶（ALK）活性或二者组合的抑制有响应的癌症和其他疾病、症状或紊乱的方法。
• Paclitaxel enhancer compounds
  申请人：Koya Keizo

  公开号：US20080214655A1

  公开（公告）日：2008-09-04

  Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R 7 R 8 )—. R 1 and R 2 are independently an aryl group or a substituted aryl group, R 3 and R 4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 5 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R 7 and R 8 are each independently —H, an aliphatic or substituted aliphatic group, or R 7 is —H and R 8 is a substituted or unsubstituted aryl group, or, R 7 and R 8 , taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.

  本发明揭示了一种由结构式（I）表示的化合物： 其中，Y是共价键，苯基或取代或未取代的直链烃基团。此外，Y与其连接的两个>C=Z基团一起，是取代或未取代的芳香族基团。优选地，Y是共价键或—C（R7R8）—。R1和R2分别是芳基基团或取代芳基基团，R3和R4分别是—H、脂肪基、取代脂肪基、芳基或取代芳基。R5-R6分别是—H、脂肪基、取代脂肪基、芳基或取代芳基。R7和R8各自独立地是—H、脂肪基或取代脂肪基，或者R7是—H，R8是取代或未取代的芳基基团，或者R7和R8一起是C2-C6取代或未取代的烷基基团。Z是═O或═S。本发明还揭示了包含本发明化合物和药学可接受的载体或稀释剂的制药组合物。本发明还揭示了一种通过将Paclitaxel或Paclitaxel类似物与结构式（I）的化合物联合给予受试者治疗癌症的方法。